Evidence map›Paper›PMID 36177959›Full record

ArticleCPT: pharmacometrics & systems pharmacology2022

Model enhanced reinforcement learning to enable precision dosing: A theoretical case study with dosing of propofol.

Benjamin Ribba, Dominic Stefan Bräm, Paul Gabriel Baverel, Richard Wilson Peck

Abstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Benjamin RibbaRoche Pharma Research and Early Development (pRED), F. Hoffmann La Roche Ltd., Basel, Switzerland.
Dominic Stefan BrämRoche Pharma Research and Early Development (pRED), F. Hoffmann La Roche Ltd., Basel, Switzerland.ORCID 0000-0001-9094-8361
Paul Gabriel BaverelRoche Pharma Research and Early Development (pRED), F. Hoffmann La Roche Ltd., Basel, Switzerland.ORCID 0000-0002-2461-5849
Richard Wilson PeckRoche Pharma Research and Early Development (pRED), F. Hoffmann La Roche Ltd., Basel, Switzerland.ORCID 0000-0003-1018-9655

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extending the potential of precision dosing requires evaluating methodologies offering more flexibility and higher degree of personalization. Reinforcement learning (RL) holds promise in its ability to integrate multidimensional data in an adaptive process built toward efficient decision making centered on sustainable value creation. For general anesthesia in intensive care units, RL is applied and automatically adjusts dosing through monitoring of patient's consciousness. We further explore the problem of optimal control of anesthesia with propofol by combining RL with state-of-the-art tools used to inform dosing in drug development. In particular, we used pharmacokinetic-pharmacodynamic (PK-PD) modeling as a simulation engine to generate experience from dosing scenarios, which cannot be tested experimentally. Through simulations, we show that, when learning from retrospective trial data, more than 100 patients are needed to reach an accuracy within the range of what is achieved with a standard dosing solution. However, embedding a model of drug effect within the RL algorithm improves accuracy by reducing errors to target by 90% through learning to take dosing actions maximizing long-term benefit. Data residual variability impacts accuracy while the algorithm efficiently coped with up to 50% interindividual variability in the PK and 25% in the PD model's parameters. We illustrate how extending the state definition of the RL agent with meaningful variables is key to achieve high accuracy of optimal dosing policy. These results suggest that RL constitutes an attractive approach for precision dosing when rich data are available or when complemented with synthetic data from model-based tools used in model-informed drug development.

Indexed as

PropofolComputer SimulationHumansModels, TheoreticalReinforcement, PsychologyRetrospective StudiesPropofol

Identifiers

PMID36177959
PMCPMC9662205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.